Skip to the text Start Names & status Tissue repair The briefings Costs Questions Evidence briefing # Match the proof to the claim. “Studied” leaves a lot unsaid. Ask what was tested, who was involved and what the result can support. Evidence file · September 26, 2026. In this briefing - Pin down the promised result - BPC-157: too little is known about harm in people - A meeting is not a product decision - A government drug code does not mean approval - Put the evidence into your visit ## Pin down the promised result Ask what “repair” means in this offer. Less pain? Better movement? A change on a scan? Those are different questions. Ask to see the study behind the exact claim. Find out whether it involved people or only animals or cells. Ask whether the substance, its form and the problem studied match the proposal in front of you. ## BPC-157: too little is known about harm in people The Food and Drug Administration (FDA), the US drug regulator, has flagged limited human safety information for BPC-157. In information checked September 26, 2026, FDA said it did not have enough evidence to know whether the proposed BPC-157 uses would harm people. Not knowing enough about harm is not evidence that BPC-157 helps healing. ## A meeting is not a product decision ### The agenda A panel advising FDA met on July 23–24, 2026 to discuss adding raw ingredients, including BPC-157 and TB-500, to the list allowed for making medicines to order. ### The staff position Before the meeting, FDA staff recommended leaving those ingredients off the list; this was a recommendation, not a final decision. ### What this means for getting a medicine No written FDA record showing how the panel voted was found as of September 26, 2026, so no vote outcome is given here. Even a vote in favor would only advise FDA; it would not give your pharmacy permission to use an ingredient. To change the list, FDA must publish a proposed rule, allow public comments and make a final rule, under the process checked September 26, 2026. ## A government drug code does not mean approval A National Drug Code is an identification code used in a government drug directory. Having the code is no proof of FDA approval for that medicine; FDA information checked September 26, 2026 explains this limit. For any approval claim, ask to see the exact product and the permitted use. A code on a page is not that answer. ## Put the evidence into your visit Save the link or print the claim. Ask the doctor or other health professional assessing you what the result means for your own problem and what remains unknown. Bring a set of clear questions ## Keep a question from this briefing Write something to take into the conversation. Your note for this page Saved notes stay in this browser. This box sends nothing to the site. Save note here Clear saved note Saving notes needs JavaScript in this browser. ## Endnotes for this chapter - FDA: ingredient concerns and missing information The source for the agency’s uncertainty about harm. - FDA advisory meeting materials Read what the panel was asked to discuss about ingredients for medicines made to order. - FDA staff briefing for the meeting The staff recommendation and the need for a separate final decision. - FDA: what a drug code means The limits of a directory entry. Return to the orientation Tissue repair, read closely. Start here Names & status Evidence Getting care Costs Cautions License checks Questions These briefings help frame care questions. This site operates no clinic and sells no medicines.